基于 DNA 超分子水凝胶的保护性 NK 细胞储库用于增强三阴性乳腺癌治疗
Protective NK Cell Reservoir Based on DNA Supramolecular Hydrogel for Enhanced Triple-Negative Breast Cancer Therapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
间质 TIL（肿瘤浸润淋巴细胞）和 TNBC-DX 在三阴性乳腺癌中提供互补的预后信息
英文原题：Stromal tumor infiltrating lymphocytes and TNBC-DX provide complementary prognostic information in triple-negative breast cancer.
查看英文原题
Stromal tumor infiltrating lymphocytes and TNBC-DX provide complementary prognostic information in triple-negative breast cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
对新辅助系统治疗达到病理完全缓解（pCR）的三阴性乳腺癌（TNBC）患者生存良好，而存在残留病灶的患者复发风险高。间质TIL（肿瘤浸润淋巴细胞）（sTILs）和 TNBC-DX 均可预测 TNBC 的 pCR。这两个生物标志物是否提供互补信息尚未得到验证。
我们在 MMJ-CAR-2014-01 研究（NCT01560663）中接受多西他赛-卡铂（TCb）治疗的 TNBC 患者，以及 NeoPACT 试验（NCT03639948）中接受 TCb 联合帕博利珠单抗（TCb+Pem）治疗的患者中，评估了 sTILs 和 TNBC-DX。在接受 TCb+Pem 治疗的患者中，sTILs 和 TNBC-DX 均可独立预测 pCR。sTILs ≥ 30% 且 TNBC-DX pCR-high 基因组评分的患者在接受 TCb+Pem 治疗时 pCR 率达到 91.3%。结合 sTILs 和 TNBC-DX 的整合分类识别出 NeoPACT 队列中约 40% 的患者，其 pCR 率超过 85%。该整合分类对接受 TCb+Pem 治疗患者的无事件生存期具有预后价值。整合 sTILs 和 TNBC-DX 可能有助于化学免疫治疗的升阶梯和降阶梯试验。
展开英文摘要原文
Patients with triple-negative breast cancer (TNBC) who achieve pathologic complete response (pCR) to neoadjuvant systemic therapy have favorable survival, while those with residual disease have high recurrence risk. Stromal tumor infiltrating lymphocytes (sTILs) and TNBC-DX both predict pCR in TNBC. Whether these 2 biomarkers provide complementary information has not been tested.
We evaluated sTILs and TNBC-DX in TNBC patients treated with docetaxel-carboplatin (TCb) on the MMJ-CAR-2014-01 study (NCT01560663) or TCb plus pembrolizumab (TCb+Pem) on the NeoPACT trial (NCT03639948). sTILs and TNBC-DX independently predicted pCR in patients treated with TCb+Pem. Patients with sTILs ≥ 30% and a TNBC-DX pCR-high genomic score achieved a pCR rate of 91.
3% with TCb+Pem. An integrated classification incorporating sTILs and TNBC-DX identified approximately 40% of the NeoPACT cohort with a pCR rate exceeding 85%. The integrated classification was prognostic for event-free survival in patients treated with TCb+Pem. Integrating sTILs and TNBC-DX may facilitate chemoimmunotherapy escalation and de-escalation trials.
论文信息
- 作者
- Stecklein SR、Martín M、Villacampa G、Del Monte-Millan M、Yoder R、Pathak H、Cobo S、Brasó-Maristany F
- 第一作者单位
- Department of Radiation Oncology, University of Kansas Medical Center, Kansas City, KS, United States.United States
- 通讯作者单位
- The University of Kansas Cancer Center, Kansas City, KS, United States.United States
- 期刊
- Journal of the National Cancer Institute2026 Feb 1
- 原文标识
- PubMed 40600921 · DOI 10.1093/jnci/djaf162
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →